|1.||Brodsky, Marina: 2 articles (08/2010 - 07/2010)|
|2.||Christ, George J: 2 articles (08/2010 - 07/2010)|
|3.||Gratzke, Christian: 2 articles (08/2010 - 07/2010)|
|4.||Andersson, Karl-Erik: 2 articles (08/2010 - 07/2010)|
|5.||Füllhase, Claudius: 2 articles (08/2010 - 07/2010)|
|6.||Soler, Roberto: 2 articles (08/2010 - 07/2010)|
|7.||Wood, N: 2 articles (09/2009 - 01/2009)|
|8.||Sachse, R: 2 articles (09/2009 - 01/2009)|
|9.||Sul, Chong Koo: 1 article (01/2015)|
|10.||Shin, Ju Hyun: 1 article (01/2015)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
03/01/2011 - "Fesoterodine, a new antimuscarinic for the treatment of overactive bladder, is rapidly and extensively hydrolyzed by nonspecific esterases to its principal active moiety, 5-hydroxymethyl tolterodine (5-HMT). "
09/01/2009 - "Fesoterodine, a new antimuscarinic agent for overactive bladder, undergoes immediate and extensive hydrolysis by nonspecific esterases to 5-hydroxymethyl tolterodine (5-HMT), the metabolite principally responsible for its antimuscarinic activity. "
01/01/2009 - "This review highlights the design and development of fesoterodine (Toviaz) as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), which is also the active metabolite of tolterodine, for the treatment of overactive bladder (OAB). "
10/01/1997 - "PNU-200577 (labcode DD 01 [(R)-N, N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine ) is a major pharmacologically active metabolite of tolterodine, a new muscarinic receptor antagonist intended for the treatment of an overactive bladder. "
08/01/2010 - "We assessed the effects of intrathecal 5-hydroxymethyl tolterodine, an active metabolite of fesoterodine, in obstructed and nonobstructed rats, and of combined intrathecal 5-hydroxymethyl tolterodine/doxazosin in a rat model of partial urethral obstruction. "
08/01/2010 - "Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction."
|3.||Body Weight (Weight, Body)
07/01/2010 - "After a 1-h period either 5-hydroxymethyl tolterodine (5-HMT, the active metabolite of fesoterodine, previously known as SPM 7605), doxazosin or a combination of both, was given intravenously (0.1 mg/kg body weight), and cystometry was continued for another 45 min. Fifteen healthy, age-matched rats served as a control. "
|4.||Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
|5.||Brain-Derived Neurotrophic Factor (BDNF)
|6.||Granulocyte Colony-Stimulating Factor (G-CSF)
|7.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)